Factor IX gene therapy - Valentis
Alternative Names: Haemophilia B gene therapy - ValentisLatest Information Update: 24 Oct 2021
Price :
$50 *
At a glance
- Originator Valentis
- Developer Urigen Pharmaceuticals
- Class Blood coagulation factors; Coagulants; Gene therapies
- Mechanism of Action Factor IX stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Haemophilia B
Most Recent Events
- 25 Jan 2017 Discontinued - Preclinical for Haemophilia B in USA (IM)
- 03 Apr 2002 Suspended - Preclinical for Haemophilia B in USA (IM)
- 24 May 2001 Factor IX gene therapy is available for licensing (http://www.valentis.com/)